December 08, 2022
KSQ Appoints Mahesh Karande to its Board of Directors
September 23, 2022
KSQ Therapeutics Announces Leadership and Board Additions
March 22, 2022
KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting
November 13, 2021
SITC Poster Presentation: "Development of KSQ-001, an Engineered TIL (eTIL®) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1"
November 12, 2021
2021 SITC Poster
September 22, 2021
KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 14, 2021
KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors
May 13, 2021
KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer
March 10, 2021
KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
January 25, 2021
KSQ® Therapeutics Appoints Qasim Rizvi, MB ChB., M.B.A., as Chief Executive Officer
January 13, 2021
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies
October 24, 2020
KSQ® Therapeutics Presents First Preclinical Data for KSQ-4279, a Novel USP1 Inhibitor, for the Treatment of BRCA-Deficient Cancers
September 24, 2020
KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
June 22, 2020
AACR Poster Presentation: "KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors
December 04, 2019
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs
December 03, 2019
KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs
November 12, 2019
KSQ Therapeutics Enhances Board of Directors with Two Appointments
October 28, 2019
KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine
October 15, 2019
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
September 25, 2018
KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors
October 02, 2017
KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development
© 2023 KSQ Therapeutics, Inc. All rights reserved.